BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (January 2020)

16 slides from BioSpecifics Technologies's investor presentation, Jan 13, 2020

  1. Slide 1: Building a next-generation company upon the foundation of our collagenase-based therapies

    Exhibit 99.1 Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020Exhibit 99.1 Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Deep CCH Commercial and Development Pipeline

    Deep CCH Commercial and Development Pipeline Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a specific collagenase formulation, collagenase clostridium histolyticum (CCH) Collagenases are Collagen is the main structural Local accumulat

  4. Slide 4: Multiple Conditions Associated with Collagen Accumulation

    Multiple Conditions Associated with Collagen Accumulation Approved indications, • Dupuytren’s contracture marketed as XIAFLEX • Peyronie’s disease • Cellulite Filed for FDA approval • Adhesive Capsulitis Potential future (frozen shoulder) indications include • Plantar Fibromatosis • Uterine Fibroids

  5. Slide 5: Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives

    Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives Profitable with lean corporate structure and strong balance sheet Seeking to partner with companies that possess ~$98M $9.4M 0 interesting new technologies in cash as of 9/30/19 3Q19 royalties Debt and products in rela

  6. Slide 6: Diverse Development Pipeline

    Diverse Development Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed APPROVED INDICATIONS Dupuytren’s Contracture Peyronie’s Disease FILED FOR APPROVAL Cellulite POTENTIAL FUTURE INDICATIONS Adhesive Capsulitis Uterine Fibroids Plantar Fibromatosis Source: Endo International plc 6Div

  7. Slide 7: Marketed XIAFLEX Indications

    ® Marketed XIAFLEX Indications 7® Marketed XIAFLEX Indications 7

  8. Slide 8: Peyronie's Disease

    Peyronie’s Disease • Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases Characterized by presence • In some mild cases, the plaque can resolve of a collagen plaque on spontaneously without medical intervention the shaft of the penis • In severe cases,

  9. Slide 9: Dupuytren's Contracture

    Dupuytren’s Contracture • Onset is characterized by the formation of nodules at the juncture between the fingers and palm that Deforming condition of are composed primarily of collagen the hand in which one • As the disease progresses, collagen nodules begin to or more fingers contract form a cord c

  10. Slide 10: CCH Development Pipeline

    CCH Development Pipeline 10CCH Development Pipeline 10

  11. Slide 11: Cellulite

    Cellulite • Affects ~85-90% of post-pubertal females • Currently no FDA approved pharmaceutical Skin dimpling occurring products to address fibrous septae primarily mainly on the buttocks, composed of collagen thighs and lower abdomen • Total U.S. aesthetics market $15B, and arms total U.S. aestheti

  12. Slide 12: Uterine Fibroids

    Uterine Fibroids • Cause pelvic discomfort and pain, decreased fertility, pregnancy complications, increased rate Benign tumors in the of miscarriage, uterine bleeding, prolonged reproductive tract that menstrual bleeding and frequent urination contain large amounts • Leading cause of hysterectomies

  13. Slide 13: BSTC Corporate Overview

    BSTC Corporate Overview 13BSTC Corporate Overview 13

  14. Slide 14: Profitable on an Ongoing Basis: Financial Highlights from 3Q19

    Profitable on an Ongoing Basis: Financial Highlights from 3Q19 For the nine months ended (unaudited) 09/30/2019 09/30/2018 Cash and equivalents, and investments $98,351,545 $76,978,545 Income Statement Revenues $26,424,380 $23,108,264 Other income 1,471,489 947,997 Costs and expenses (7,067,404) (6,

  15. Slide 15: Corporate Outlook and Upcoming Milestones

    Corporate Outlook and Upcoming Milestones Continue to receive royalty Opportunistic about Continue to advance revenues from partner Endo Business Development diverse development for both marketed XIAFLEX opportunities pipeline indications; Peyronie’s • Expanding BioSpecifics • BLA for cellulite acce

  16. Slide 16: Building a next-generation company upon the foundation of our collagenase-based therapies

    Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020

Biospecifics Technologies — Investor Presentation (January 2020) on 6ix